Photos of Bristol Myers Squibb and Cellares from LinkedIn
Apr 26, 2024, 19:35
We are pleased to announce a worldwide capacity reservation and supply agreement with Cellares for the manufacture of CAR T cell therapies – Bristol Myers Squibb
Bristol Myers Squibb shared a post on LinkedIn:
“We are pleased to announce a worldwide capacity reservation and supply agreement with Cellares for the manufacture of CAR T cell therapies, giving us access to a next-generation fully automated, end-to-end cell therapy manufacturing platform. As part of the agreement, Cellares will optimize and automate select BMS CAR T cell therapies onto its manufacturing platform, the Cell Shuttle. We look forward to our continued work with Cellares and to the promise this agreement will bring for patients benefiting from CAR T therapies.”
Source: Bristol Myers Squibb/LinkedIn
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
May 30, 2025, 15:11
May 30, 2025, 14:55
May 30, 2025, 14:31